Effect of exercise on taxane chemotherapy–induced peripheral neuropathy in women with breast cancer: A randomized controlled trial

Journal article


Bland, Kelcey A., Kirkham, Amy A., Bovard, Joshua, Shenkier, Tamara, Zucker, David, McKenzie, Donald C., Davis, Margot K., Gelmon, Karen A. and Campbell, Kristin L.. (2019). Effect of exercise on taxane chemotherapy–induced peripheral neuropathy in women with breast cancer: A randomized controlled trial. Clinical Breast Cancer. 19(6), pp. 411 - 422. https://doi.org/10.1016/j.clbc.2019.05.013
AuthorsBland, Kelcey A., Kirkham, Amy A., Bovard, Joshua, Shenkier, Tamara, Zucker, David, McKenzie, Donald C., Davis, Margot K., Gelmon, Karen A. and Campbell, Kristin L.
Abstract

Background Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse effect of taxanes. We sought to evaluate the effect of exercise on taxane CIPN in women with breast cancer. Patients and Methods Women (n = 27) were randomized to immediate exercise (IE, during taxane chemotherapy) or delayed exercise (DE, after chemotherapy). Supervised aerobic, resistance, and balance training was offered 3 days a week for 8-12 weeks. CIPN symptoms and quality of life were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30 and CIPN20 (scored from 0 to 100). The percentage of participants reporting moderate to severe sensory symptoms (‘3/4’ or ‘4/4’ for CIPN20 sensory items) was also evaluated, along with clinical sensory testing at the lower limb (vibration sense and pinprick). Taxane treatment adherence, including relative dose intensity, was extracted from patient medical records. Assessments occurred at: baseline (before taxane chemotherapy), pre-cycle 4 (before the final taxane cycle), the end of chemotherapy, and follow-up (10-15 weeks after chemotherapy). Results No differences in the EORTC QLQ CIPN20 symptom scores were detected between groups at any time point. At pre-cycle 4, there was a significant difference between groups in patient-reported moderate to severe numbness in the toes or feet (IE: n = 1, 9%, DE: n = 7, 50%, P = .04) and impaired vibration sense in the feet (IE: n = 2, 18%, DE: n = 10, 83%, P < .01). Overall global health status/quality of life was higher in IE compared to DE at the end of chemotherapy (P = .05), yet both groups had worse CIPN20 sensory (Δ24.3 ± 4.6, P < .01) and motor symptom scores (Δ10.5 ± 1.9, P < .01) relative to baseline. By the end of chemotherapy, no differences between groups were found for moderate to severe numbness in the toes or feet (P = 1.0) or impaired vibration sense in the feet (P = .71). More IE participants received ≥ 85% relative dose intensity (IE: n = 12, 100%, DE: n = 10, 67%, P < .05). Conclusion Exercise may attenuate CIPN over the course of taxane chemotherapy and possibly improve taxane adherence in women with breast cancer. These findings, as well as whether exercise can attenuate CIPN by the end of taxane chemotherapy, should be confirmed in larger trials.

KeywordsAerobic exercise; Breast neoplasm; Polyneuropathy; Resistance training; Quality of life
Year2019
JournalClinical Breast Cancer
Journal citation19 (6), pp. 411 - 422
PublisherElsevier Inc.
ISSN1526-8209
Digital Object Identifier (DOI)https://doi.org/10.1016/j.clbc.2019.05.013
Scopus EID2-s2.0-85073023609
Page range411 - 422
Research GroupMary MacKillop Institute for Health Research
Publisher's version
File Access Level
Controlled
Place of publicationUnited States of America
Permalink -

https://acuresearchbank.acu.edu.au/item/86x37/effect-of-exercise-on-taxane-chemotherapy-induced-peripheral-neuropathy-in-women-with-breast-cancer-a-randomized-controlled-trial

Restricted files

Publisher's version

  • 26
    total views
  • 0
    total downloads
  • 3
    views this month
  • 0
    downloads this month
These values are for the period from 19th October 2020, when this repository was created.

Export as